Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Oct 28 - Nov 2
Ahmad et al., 2020
Heliyon 10 (16), e36131
Initially approved to treat diabetes, glucagon-like peptide-1 (GLP-1) drugs are being heralded to address obesity and, more recently, obstructive sleep apnea (OSA)
The basal insulin dose was decreased by 20% at randomization, and Victoza was initiated at 0.6 mg/day and was titrated to 1.2 mg and 1.8 mg over the course of 2-3 weeks based on tolerability and an average fasting plasma glucose goal of 110 mg/dL
US$ 25.52
:max_bytes(150000):strip_icc()/GettyImages-1299286851-18ab6e02931940ad963dda93851b6dc7.jpg)
US$ 25.10
US$ 28.56
US$ 26.84
US$ 28.17
US$ 25.55
US$ 28.13
